Related references
Note: Only part of the references are listed.Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B)
Yukari Tsubata et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)
Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma
Floriana Bardaro et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2022)
Metabolic and electrolyte abnormalities as risk factors in drug-induced long QT syndrome
Clifford Tebay et al.
BIOPHYSICAL REVIEWS (2022)
FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma
Elaine Chang et al.
CLINICAL CANCER RESEARCH (2022)
Interplay between Zn2+ Homeostasis and Mitochondrial Functions in Cardiovascular Diseases and Heart Ageing
Siarhei A. Dabravolski et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
TRPM7 Modulates Human Pancreatic Stellate Cell Activation
Julie Auwercx et al.
CELLS (2022)
A pan-cancer-bioinformatic-based literature review of TRPM7 in cancers
Hengrui Liu et al.
PHARMACOLOGY & THERAPEUTICS (2022)
Serum Magnesium, Blood Pressure, and Risk of Hypertension and Chronic Kidney Disease Progression in the CRIC Study
Simon Correa et al.
HYPERTENSION (2021)
Platelet derived growth factor-A (Pdgf-a) gene transfer modulates scar composition and improves left ventricular function after infarction
N. Fairooj Rashid et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)
Role of TRPM7 in cardiac fibrosis: A potential therapeutic target (Review)
Feng Hu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2021)
Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment
Guihong Liu et al.
CELL PROLIFERATION (2021)
Association of Cumulative Systolic Blood Pressure With Long-Term Risk of Cardiovascular Disease and Healthy Longevity Findings From the Lifetime Risk Pooling Project Cohorts
Orna Reges et al.
HYPERTENSION (2021)
Heart Failure With Targeted Cancer Therapies Mechanisms and Cardioprotection
Virginia S. Hahn et al.
CIRCULATION RESEARCH (2021)
Carvacrol alleviates liver fibrosis by inhibiting TRPM7 and modulating the MAPK signaling pathway
Shiyi Cai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel
Tian Jia et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)
Case Report: QT Prolongation and Abortive Sudden Death Observed in an 85-Year-Old Female Patient With Advanced Lung Cancer Treated With Tyrosine Kinase Inhibitor Osimertinib
Moe Kondo et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2021)
Role of TRPM7 kinase in cancer
Selena Meng et al.
CELL CALCIUM (2021)
Modulation of the Cardiac Myocyte Action Potential by the Magnesium-Sensitive TRPM6 and TRPM7-like Current
Asfree Gwanyanya et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study
Yoon-Koo Kang et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Possible involvement of zinc deficiency in epidermal growth factor receptor inhibitor-induced xerotic dermatitis
Mikiko Tohyama et al.
JOURNAL OF DERMATOLOGY (2021)
Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC
Sarah Waliany et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2021)
Evidence for the expression of TRPM6 and TRPM7 in cardiomyocytes from all four chamber walls of the human heart
Inga Andriule et al.
SCIENTIFIC REPORTS (2021)
Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma
Elif Hindie
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Osimertinib-induced cardiac failure with QT prolongation and torsade de pointes in a patient with advanced pulmonary adenocarcinoma
Saori Ikebe et al.
INTERNATIONAL CANCER CONFERENCE JOURNAL (2021)
Chanzyme TRPM7 protects against cardiovascular inflammation and fibrosis
Francisco J. Rios et al.
CARDIOVASCULAR RESEARCH (2020)
Dasatinib can Impair Left Ventricular Mechanical Function But May Lack Proarrhythmic Effect: A Proposal of Non-clinical Guidance for Predicting Clinical Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors
Hiroko Izumi-Nakaseko et al.
CARDIOVASCULAR TOXICOLOGY (2020)
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Peter T. Harrison et al.
SEMINARS IN CANCER BIOLOGY (2020)
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
R. K. Murthy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inhibition of TRPM7 blocks MRTF/SRF-dependent transcriptional and tumorigenic activity
Sandra Voringer et al.
ONCOGENE (2020)
EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and in Vitro Rat Studies
Ali Alhoshani et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
Kohei Shitara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Epidermal growth factor signaling through transient receptor potential melastatin 7 cation channel regulates vascular smooth muscle cell function
Zhi-Guo Zou et al.
CLINICAL SCIENCE (2020)
The role of TRPM7 in vascular calcification: Comparison between phosphate and uremic toxin
Chien-Te Lee et al.
LIFE SCIENCES (2020)
Cardiotoxicity Surveillance and Risk of Heart Failure During HER2 Targeted Therapy
Anthony F. Yu et al.
JACC: CARDIOONCOLOGY (2020)
Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
Kei Kunimasa et al.
JACC: CARDIOONCOLOGY (2020)
Effects of Magnesium Deficiency on Mechanisms of Insulin Resistance in Type 2 Diabetes: Focusing on the Processes of Insulin Secretion and Signaling
Krasimir Kostov
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
TRPM7, Magnesium, and Signaling
Zhi-Guo Zou et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
TRPM7 channel inhibition exacerbates pulmonary arterial hypertension through MEK/ERK pathway
Junhui Xing et al.
AGING-US (2019)
Ripretinib turns off the switch in GIST
M. Teresa Villanueva
NATURE REVIEWS CANCER (2019)
PDGFR-β Signaling Regulates Cardiomyocyte Proliferation and Myocardial Regeneration
Zhang Yue et al.
CELL REPORTS (2019)
Magnesium Regulates Endothelial Barrier Functions through TRPM7, MagT1, and S1P1
Donghui Zhu et al.
ADVANCED SCIENCE (2019)
Leptin Induces Hypertension Acting on Transient Receptor Potential Melastatin 7 Channel in the Carotid Body
Mi-Kyung Shin et al.
CIRCULATION RESEARCH (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Osimertinib-Induced Cardiotoxicity A Retrospective Review of the FDA Adverse Events Reporting System (FAERS)
Kartik Anand et al.
JACC: CARDIOONCOLOGY (2019)
Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results
Robert J. Motzer et al.
EUROPEAN UROLOGY (2018)
Prevalence of Zinc Deficiency in Cardiac Surgery Patients
Lesley A. Braun et al.
HEART LUNG AND CIRCULATION (2018)
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations
Tony S. Mok et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Dacomitinib in NSCLC: a positive trial with little clinical impact
Alfredo Addeo
LANCET ONCOLOGY (2018)
Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges
Ramesh Butti et al.
MOLECULAR CANCER (2018)
Mechanisms of receptor tyrosine kinase activation in cancer
Zhenfang Du et al.
MOLECULAR CANCER (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors
Stephen J. H. Dobbin et al.
HEART (2018)
Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
Meng-Chiao Hsieh et al.
SCIENTIFIC REPORTS (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
TRPM7 is overexpressed in bladder cancer and promotes proliferation, migration, invasion and tumor growth
Sheng-Lin Gao et al.
ONCOLOGY REPORTS (2017)
AstragalosideIV against cardiac fibrosis by inhibiting TRPM7 channel
Jun Lu et al.
PHYTOMEDICINE (2017)
High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Arun Sharma et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
TRPM7 kinase activity is essential for T cell colonization and alloreactivity in the gut
Andrea Romagnani et al.
NATURE COMMUNICATIONS (2017)
Leukocyte TRP channel gene expressions in patients with non-valvular atrial fibrillation
Irfan V. Duzen et al.
SCIENTIFIC REPORTS (2017)
Mass Spectrometric Analysis of TRPM6 and TRPM7 Phosphorylation Reveals Regulatory Mechanisms of the Channel-Kinases
Na Cai et al.
SCIENTIFIC REPORTS (2017)
The crucial role of the TRPM7 kinase domain in the early stage of amelogenesis
Kayoko Ogata et al.
SCIENTIFIC REPORTS (2017)
Evaluation of the effect of the EGFR antibody-drug conjugate ABT-414 on QT interval prolongation in patients with advanced solid tumors likely to over-express EGFR
Wijith P. Munasinghe et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis
Husam Abdel-Qadir et al.
CANCER TREATMENT REVIEWS (2017)
Hypomagnesemia in Type 2 Diabetes: A Vicious Circle?
Lisanne M. M. Gommers et al.
DIABETES (2016)
Vascular Fibrosis in Aging and Hypertension: Molecular Mechanisms and Clinical Implications
Adam Harvey et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
Jose Luis Zamorano et al.
EUROPEAN HEART JOURNAL (2016)
Cardiovascular adverse effects of targeted antiangiogenic drugs: mechanisms and management
Srinath Sundararajan et al.
FUTURE ONCOLOGY (2016)
Effects of Magnesium Supplementation on Blood Pressure A Meta-Analysis of Randomized Double-Blind Placebo-Controlled Trials
Xi Zhang et al.
HYPERTENSION (2016)
Aldosterone Upregulates Transient Receptor Potential Melastatin 7 (TRPM7)
William C. Valinsky et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Adaptive Randomization of Neratinib in Early Breast Cancer
J. W. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
TRPM7 regulates vascular endothelial cell adhesion and tube formation
Zhao Zeng et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2015)
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
Pooja Ghatalia et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
EGFR-TKI, Erlotinib, Causes Hypomagnesemia, Oxidative Stress, and Cardiac Dysfunction: Attenuation by NK-1 Receptor Blockade
I. Tong Mak et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Josep Tabernero et al.
LANCET ONCOLOGY (2015)
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
T. K. Choueiri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
John A. Wells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion
Wen-Liang Chen et al.
ONCOTARGET (2015)
QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
P. Ghatalia et al.
BRITISH JOURNAL OF CANCER (2015)
Cholesterol-induced activation of TRPM7 regulates cell proliferation, migration, and viability of human prostate cells
Yuyang Sun et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2014)
Hypertension Due to Antiangiogenic Cancer Therapy With Vascular Endothelial Growth Factor Inhibitors: Understanding and Managing a New Syndrome
Heather Yvonne Small et al.
CANADIAN JOURNAL OF CARDIOLOGY (2014)
TRPM7 is involved in angiotensin II induced cardiac fibrosis development by mediating calcium and magnesium influx
Yang Yu et al.
CELL CALCIUM (2014)
Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis
Wei-Xiang Qi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Mg2+- and ATP-dependent inhibition of transient receptor potential melastatin 7 by oxidative stress
Hana Inoue et al.
FREE RADICAL BIOLOGY AND MEDICINE (2014)
Transient Receptor Potential Melastatin 7 (TRPM7) Contributes to H2O2-Induced Cardiac Fibrosis via Mediating Ca2+ Influx and Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Activation in Cardiac Fibroblasts
Jin-Lei Guo et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
Ian E. Krop et al.
LANCET ONCOLOGY (2014)
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Hansjochen Wilke et al.
LANCET ONCOLOGY (2014)
Afatinib in NSCLC harbouring EGFR mutations
Filippo de Marinis et al.
LANCET ONCOLOGY (2014)
An update on cardio-oncology
Joerg Herrmann et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2014)
Cellular and Developmental Biology of TRPM7 Channel-Kinase: Implicated Roles in Cancer
Nelson Yee et al.
Cells (2014)
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer
M. K. Boisen et al.
ANNALS OF ONCOLOGY (2013)
Timing of Myocardial Trpm7 Deletion During Cardiogenesis Variably Disrupts Adult Ventricular Function, Conduction, and Repolarization
Rajan Sah et al.
CIRCULATION (2013)
Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials
Guru Sonpavde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Ion channel-kinase TRPM7 is required for maintaining cardiac automaticity
Rajan Sah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
TRPM7 channel regulates PDGF-BB-induced proliferation of hepatic stellate cells via PI3K and ERK pathways
Ling Fang et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2013)
Regorafenib Induces Rapid and Reversible Changes in Plasma Nitric Oxide and Endothelin-1
Nilka de Jesus-Gonzalez et al.
AMERICAN JOURNAL OF HYPERTENSION (2012)
Silencing TRPM7 mimics the effects of magnesium deficiency in human microvascular endothelial cells
Erika Baldoli et al.
ANGIOGENESIS (2012)
Evidence for functional expression of TRPM7 channels in human atrial myocytes
Yan-Hui Zhang et al.
BASIC RESEARCH IN CARDIOLOGY (2012)
Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma
Nelson S. Yee et al.
CANCER LETTERS (2012)
Identification of Ser/Thr phosphorylation sites in the C2-domain of phospholipase C γ2 (PLCγ2) using TRPM7-kinase
Francina Deason-Towne et al.
CELLULAR SIGNALLING (2012)
Upregulation of TRPM7 Channels by Angiotensin II Triggers Phenotypic Switching of Vascular Smooth Muscle Cells of Ascending Aorta
Zheng Zhang et al.
CIRCULATION RESEARCH (2012)
Sunitinib-Induced Systemic Vasoconstriction in Swine Is Endothelin Mediated and Does Not Involve Nitric Oxide or Oxidative Stress
Mariette H. W. Kappers et al.
HYPERTENSION (2012)
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Price To Be Paid for Two-Metal Catalysis: Magnesium Ions That Accelerate Chemistry Unavoidably Limit Product Release from a Protein Kinase
Douglas M. Jacobsen et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies
Tim Eisen et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia
Alex Kentsis et al.
NATURE MEDICINE (2012)
Aflibercept
Michael W. Stewart et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
Gunter von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Erlotinib-Mediated Inhibition of EGFR Signaling Induces Metabolic Oxidative Stress through NOX4
Kevin P. Orcutt et al.
CANCER RESEARCH (2011)
EGF enhances the migration of cancer cells by up-regulation of TRPM7
Haixia Gao et al.
CELL CALCIUM (2011)
The channel-kinase TRPM7 regulates phosphorylation of the translational factor eEF2 via eEF2-k
Anne-Laure Perraud et al.
CELLULAR SIGNALLING (2011)
Transient receptor potential ion channel Trpm7 regulates exocrine pancreatic epithelial proliferation by Mg2+-sensitive Socs3a signaling in development and cancer
Nelson S. Yee et al.
DISEASE MODELS & MECHANISMS (2011)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
Ronald B. Natale et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Role of Mg2+ ions in protein kinase phosphorylation: insights from molecular dynamics simulations of ATP-kinase complexes
Lu Yu et al.
MOLECULAR SIMULATION (2011)
Second messenger role for Mg2+ revealed by human T-cell immunodeficiency
Feng-Yen Li et al.
NATURE (2011)
The molecular biology of head and neck cancer
C. Rene Leemans et al.
NATURE REVIEWS CANCER (2011)
Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease
Abigail May Khan et al.
AMERICAN HEART JOURNAL (2010)
TRPM7-Mediated Ca2+ Signals Confer Fibrogenesis in Human Atrial Fibrillation
Jianyang Du et al.
CIRCULATION RESEARCH (2010)
Thromboembolic Events in Patients Treated with Anti-Angiogenic Drugs
Patrizia Ferroni et al.
CURRENT VASCULAR PHARMACOLOGY (2010)
Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor-Signaling Inhibitors
Emily S. Robinson et al.
HYPERTENSION (2010)
Methionine Sulfoxide Reductase B1 (MsrB1) Recovers TRPM6 Channel Activity during Oxidative Stress
Gang Cao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Importance of melastatin-like transient receptor potential 7 and magnesium in the stimulation of osteoblast proliferation and migration by platelet-derived growth factor
Elie Abed et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2009)
Evidence that TRPM7 is required for breast cancer cell proliferation
Arnaud Guilbert et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2009)
Silencing TRPM7 promotes growth/proliferation and nitric oxide production of vascular endothelial cells via the ERK pathway
Koichi Inoue et al.
CARDIOVASCULAR RESEARCH (2009)
Regulation of the novel Mg2+ transporter transient receptor potential melastatin 7 (TRPM7) cation channel by bradykinin in vascular smooth muscle cells
Glaucia E. Callera et al.
JOURNAL OF HYPERTENSION (2009)
EGF Increases TRPM6 Activity and Surface Expression
Stehanie Thebault et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer
Aninda Basu et al.
CANCER RESEARCH (2008)
Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension
Emmanuel Letavernier et al.
CIRCULATION RESEARCH (2008)
Hypomagnesaemia and risk for metabolic glucose disorders:: a 10-year follow-up study
F. Guerrero-Romero et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2008)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
Henry L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Activity of sunitinib in patients with advanced neuroendocrine tumors
Matthew H. Kulke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation
Kristopher Clark et al.
JOURNAL OF MOLECULAR BIOLOGY (2008)
Cetuximab in Head and Neck Cancer
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Massive Autophosphorylation of the Ser/Thr-Rich Domain Controls Protein Kinase Activity of TRPM6 and TRPM7
Kristopher Clark et al.
PLOS ONE (2008)
Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice
Cordelia J. Barrick et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2008)
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Tammy F. Chu et al.
LANCET (2007)
Molecularly targeted oncology therapeutics and prolongation of the QT interval
Elizabeth L. Strevel et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
NGF-induced reduction of an outward-rectifying TRPM7-like current in rat CA1 hippocampal neurons
Shun-Lian Tian et al.
NEUROSCIENCE LETTERS (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Thomas Force et al.
NATURE REVIEWS CANCER (2007)
Epidermal growth factor receptor mutations in lung cancer
Sreenath V. Sharma et al.
NATURE REVIEWS CANCER (2007)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure
I Shiojima et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Transient receptor potential melastatin 7 ion channels regulate magnesium Homeostasis in vascular smooth muscle cells - Role of angiotensin II
Y He et al.
CIRCULATION RESEARCH (2005)
Phosphorylation of annexin I by TRPM7 channel-kinase
MV Dorovkov et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer - A randomized trial
MG Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
The TRPM7 channel is inactivated by PIP2 hydrolysis
LW Runnels et al.
NATURE CELL BIOLOGY (2002)
Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis
E Kolomietz et al.
BLOOD (2001)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
Share Paper
